We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Gestational Lipid Profiles Associated with Adverse Cardiovascular Risk

By LabMedica International staff writers
Posted on 12 Jan 2021
Pregnancy has been proposed as a natural ‘stress test’ to predict the risk of cardiovascular disease (CVD) later in life. More...
The long-term effect of high blood pressure during pregnancy has been well established. Women who develop a hypertensive disorder of pregnancy such as gestational hypertension or pre-eclampsia have a 2–8 times higher risk of developing chronic hypertension and other diseases.

In pregnancy, lipid levels rise, leading to 30% higher levels of cholesterol, triglycerides and low density lipoprotein cholesterol at the end of the third term. The gestational lipid profile therefore shows resemblance to an atherogenic lipid profile. After delivery, lipid levels in general normalize to pre-pregnancy levels within three to four months.

Obstetricians and Gynecologists at the Erasmus University Medical Centre (Rotterdam, The Netherlands) and their colleagues performed an ongoing population-based prospective cohort study from early pregnancy and obtained plasma from 3,510 women from the Generation R study. The scientists measured lipid levels (total cholesterol, triglycerides and high-density lipoprotein cholesterol [HDL-c]), and low-density lipoprotein cholesterol (LDL-c), remnant cholesterol and non-HDL-c that were calculated in early pregnancy (median 13.2 weeks, 90% range [10.5 to 17.1]) and six years after pregnancy (median 6.5 years, 90% range [6.2 to 7.8]). Glucose levels, total cholesterol, triglycerides and HDL-c concentrations were measured with the Selectra E Chemistry Analyzer (Vital Scientific, Dieren, The Netherlands). Metabolic syndrome (MS) was assessed six years after pregnancy according to the NCEP/ATP3 criteria. They also examined the influence of pregnancy complications on these associations.

The scientists reported that gestational lipid levels were positively associated with corresponding lipid levels six years after pregnancy, independent of pregnancy complications. Six years after pregnancy the prevalence of MS was 10.0%; the prevalence was higher for women with a previous placental syndrome (13.5%). The most common feature of metabolic syndrome was low HDL-c (40.0%) followed by abdominal obesity (25.6%), high triglycerides (19.7%), a high blood pressure (19.0%), and high glucose levels (2.3%). Gestational triglycerides and remnant cholesterol in the highest quartile and HDL-c in the lowest quartile were associated with the highest risk for future MS, independent of smoking and body mass index.

The authors concluded that gestational lipid levels provide an insight in the future cardiovascular risk profile of women in later life. Monitoring and lifestyle intervention could be indicated in women with an unfavorable gestational lipid profile to optimize timely cardiovascular risk prevention. The study was published on December 23, 2020 in the journal BMC Medicine.

Related Links:
Erasmus University Medical Centre
Vital Scientific



Gold Member
Collection and Transport System
PurSafe Plus®
POC Helicobacter Pylori Test Kit
Hepy Urease Test
6 Part Hematology Analyzer with RET + IPF
Mispa HX 88
Rapid Molecular Testing Device
FlashDetect Flash10
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Immunology

view channel
Image: Whole-genome sequencing enables broader detection of DNA repair defects to guide PARP inhibitor cancer therapy (Photo courtesy of Illumina)

Whole-Genome Sequencing Approach Identifies Cancer Patients Benefitting From PARP-Inhibitor Treatment

Targeted cancer therapies such as PARP inhibitors can be highly effective, but only for patients whose tumors carry specific DNA repair defects. Identifying these patients accurately remains challenging,... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.